方盛製藥(603998.SH):方錦程所持2142.7203萬股將被司法拍賣
格隆匯11月17日丨方盛製藥(603998.SH)公佈,公司於近日通過公開渠道獲悉,湖北省武漢市中級人民法院(“武漢中院”)將公開拍賣公司股東方錦程持有的公司2142.7203萬股無限售流通股票,佔公司股份總數的4.99%,佔方錦程持有公司總股份的99.60%,且方錦程持有的公司股份全部處於凍結狀態。拍賣時間為2021年12月16日10時至2021年12月17日10時止(延時除外)。
此次方錦程持有的股票被武漢中院拍賣系方錦程在天風證券股份有限公司辦理的股票質押式回購業務發生違約(因其他訴訟被凍結而無法及時減持履約),武漢中院執行訴訟判決所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.